Pharmacological chaperones for enzyme enhancement therapy in genetic diseases.
Pharmacological chaperone therapy (PCT) is a rather new approach consisting in targeting incorrectly folded proteins by small molecules, thus, facilitating the correct folding of the protein and inducing a recovery of its functionality. Many diseases result from mutations on specific genes; this patent review focuses on those pathologies where PCT has a potential application for enzymatic enhancement. Rare diseases are the main area where PCT has been applied and the most advanced compounds are aiming to cure lysosomal storage disorders such as Fabry, Pompe or Gaucher. Until now, most compounds used as pharmacological chaperones were based on substrate-like chemical structures but recently new nonsubstrate-like and non-inhibitory compounds have been disclosed for Gaucher and Pompe diseases. This initiates a new era for pharmacological chaperones with more diverse chemical structures and binding modes. This review covers the patents relating to enzyme enhancement on pharmacological chaperone therapy. Only an update is presented for Gaucher disease, where PCT is highly applied and recently reviewed.
Minoryx Therapeutics S.L., TecnoCampus Mataró-Maresme. Av. Ernest Lluch 32, TCM2, 08302 Mataró, Barcelona, Spain.
Juan
J
Aymami
Xavier
X
Barril
Laura
L
Rodríguez-Pascau
Marc
M
Martinell
D000818:Animals; D003550:Cystic Fibrosis / Q000188:drug therapy; D057487:Enzyme Therapy; D006801:Humans; D016464:Lysosomal Storage Diseases / Q000188:drug therapy*; D018832:Molecular Chaperones / Q000627:therapeutic use*; D010661:Phenylketonurias / Q000188:drug therapy
D018832:Molecular Chaperones